Sex-Associated Differences in Cytomegalovirus Prevention: Prophylactic Strategy is Potentially Associated With a Strong Kidney Function Impairment in Female Renal Transplant Patients.
cytomegalovirus
gender
graft function
prevention
valganciclovir
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
02
2020
accepted:
03
11
2020
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
2
2
2021
Statut:
epublish
Résumé
Post-transplantation cytomegalovirus (CMV) syndrome can be prevented using the antiviral drug (val)ganciclovir. (Val)ganciclovir is typically administered following a prophylactic or a pre-emptive strategy. The prophylactic strategy entails early universal administration, the pre-emptive strategy, early treatment in case of infection. However, it is not clear which strategy is superior with respect to transplantation outcome; sex-specific effects of these prevention strategies are not known. We have retrospectively analyzed 540 patients from the multi-centre Harmony study along eight pre-defined visits: 308 were treated according to a prophylactic, 232 according to a pre-emptive strategy. As expected, we observed an association of prophylactic strategy with lower incidence of CMV syndrome, delayed onset and lower viral loads compared to the pre-emptive strategy. However, in female patients, the prophylactic strategy was associated with a strong impairment of glomerular filtration rate one year post-transplant (difference: -11.8 ± 4.3 ml min
Identifiants
pubmed: 33519427
doi: 10.3389/fphar.2020.534681
pii: 534681
pmc: PMC7845412
doi:
Types de publication
Journal Article
Langues
eng
Pagination
534681Informations de copyright
Copyright © 2020 Blazquez-Navarro, Dang-Heine, Bauer, Wittenbrink, Wolk, Sabat, Witzke, Westhoff, Sawitzki, Reinke, Thomusch, Hugo, Babel and Or-Guil.
Déclaration de conflit d'intérêts
OW has received research grants for clinical studies, speaker's fees, honoraria and travel expenses from Amgen, Astellas, Bristol-Myers Squibb, Chiesi, Janssen-Cilag, MSD, Novartis, Roche, Pfizer, and Sanofi. OW is supported by an unrestricted grant of the Rudolf-Ackermann-Stiftung (Stiftung für Klinische Infektiologie). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nephrology (Carlton). 2013 Dec;18(12):813-9
pubmed: 23927085
Nephrol Dial Transplant. 2012 Jan;27(1):435-43
pubmed: 21712490
Int J Mol Sci. 2018 Dec 08;19(12):
pubmed: 30544783
Clin Kidney J. 2018 Aug;11(4):564-573
pubmed: 30094022
Transplantation. 2012 Aug 27;94(4):396-402
pubmed: 22836134
Am J Transplant. 2007 Mar;7(3):518-26
pubmed: 17352710
Transplantation. 2013 Dec 27;96(12):1097-103
pubmed: 24056621
Transplantation. 2010 Aug 27;90(4):412-8
pubmed: 20555305
J Nephropathol. 2015 Oct;4(4):110-5
pubmed: 26457257
Wien Klin Wochenschr. 2017 Nov;129(21-22):781-785
pubmed: 29043442
Pediatr Transplant. 2017 Feb;21(1):
pubmed: 27704725
Transpl Infect Dis. 2019 Dec;21(6):e13106
pubmed: 31081566
Clin Transplant. 2019 Aug;33(8):e13636
pubmed: 31194887
PLoS Comput Biol. 2018 May 10;14(5):e1005998
pubmed: 29746472
Am J Transplant. 2019 Sep;19(9):2457-2467
pubmed: 31220412
Am J Transplant. 2006 Sep;6(9):2134-43
pubmed: 16780548
Transplantation. 2006 Jan 27;81(2):202-6
pubmed: 16436963
J Exp Med. 2005 Apr 4;201(7):1031-6
pubmed: 15795239
Transplantation. 2001 Mar 27;71(6):764-7
pubmed: 11330539
Transplantation. 2001 Feb 15;71(3):429-32
pubmed: 11233906
Transplant Rev (Orlando). 2017 Jul;31(3):145-150
pubmed: 28262425
GMS Hyg Infect Control. 2016 Sep 27;11:Doc20
pubmed: 27730028
Transplantation. 2010 Feb 15;89(3):320-6
pubmed: 20145523
Clin J Am Soc Nephrol. 2015 Feb 6;10(2):294-304
pubmed: 25424991
Transplantation. 2012 Jan 15;93(1):61-8
pubmed: 22094954
Int J Epidemiol. 2017 Apr 1;46(2):746-755
pubmed: 28025257
Medicine (Baltimore). 2016 Feb;95(6):e2735
pubmed: 26871815
EBioMedicine. 2018 Aug;34:113-121
pubmed: 30072213
Nephrol Dial Transplant. 2007 Sep;22 Suppl 8:viii72-viii82
pubmed: 17890268
Clin Infect Dis. 2014 Mar;58(6):785-803
pubmed: 24385444
J Transl Med. 2008 Jun 09;6:29
pubmed: 18541023
Transpl Infect Dis. 2014 Jun;16(3):387-96
pubmed: 24807640
Am J Transplant. 2005 Dec;5(12):2894-900
pubmed: 16303002
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Transpl Immunol. 2009 Mar;20(4):238-42
pubmed: 19032982
Clin Infect Dis. 2006 Oct 1;43(7):869-80
pubmed: 16941368
Antimicrob Agents Chemother. 2009 Jul;53(7):3017-23
pubmed: 19307355
BMC Infect Dis. 2018 Nov 15;18(1):573
pubmed: 30442095
Lancet. 2017 Dec 17;388(10063):3006-3016
pubmed: 27871759
Am J Kidney Dis. 2011 Mar;57(3):466-75
pubmed: 21257243
Transpl Int. 2009 Jun;22(6):626-34
pubmed: 19207187
Transplantation. 2018 May;102(5):876-882
pubmed: 29166336
J Clin Epidemiol. 2001 Apr;54(4):343-9
pubmed: 11297884
Hum Immunol. 2004 May;65(5):476-85
pubmed: 15172447
Transplant Proc. 2016 Oct;48(8):2695-2699
pubmed: 27788803
Obesity (Silver Spring). 2017 Mar;25(3):626-633
pubmed: 28229547
Transplantation. 2001 May 15;71(9):1287-94
pubmed: 11397964
Am J Transplant. 2009 Nov;9 Suppl 3:S1-155
pubmed: 19845597
Transpl Infect Dis. 2016 Dec;18(6):904-912
pubmed: 27639246
Can J Kidney Health Dis. 2017 Jan 23;4:2054358116688227
pubmed: 28270929
Am J Transplant. 2017 Mar;17(3):770-781
pubmed: 27545492
Am J Transplant. 2008 May;8(5):975-83
pubmed: 18261177
Am J Transplant. 2013 Jan;13(1):136-45
pubmed: 23137180
Transplantation. 2018 Jun;102(6):900-931
pubmed: 29596116
Transplantation. 2013 Jun 27;95(12):1498-505
pubmed: 23778568
Transpl Int. 2015 Dec;28(12):1351-6
pubmed: 26138458
Am J Transplant. 2015 Sep;15(9):2431-42
pubmed: 25943855
Biogerontology. 2015 Oct;16(5):631-43
pubmed: 25732234